Self-compression Mammography in Clinical Practice (Pristina2/TR)

February 25, 2021 updated by: Arcispedale Santa Maria Nuova-IRCCS

Self-compression Mammography in Clinical Practice: A Randomized Clinical Trial Compared to Standard Compression Mammography

Every year millions of mammograms are performed worldwide, representing the primary examination for the early diagnosis of breast cancer. Despite continuous advances in medicine and technology, an aspect of mammography has not changed in over fifty years: the breast is still compressed on the detector because this allows to reduce the thickness of the breast thus improving the quality of the diagnostic image and reducing the dose of radiation necessary to obtain a clear image. Many women perceive as painful this compression, including women who have been treated for breast cancer.

Pain can discourage asymptomatic women to present themselves periodically to screening mammography, while an increasing number of women in follow-up after conservative surgery have to withstand the pain caused by mammography.

Some studies mention various factors that are responsible for pain when performing mammography: breast sensitivity, anxiety level, expected pain and staff attitude. Some studies have also identified breast density, breast volume and menstrual phase as other influencing factors, although not all studies support these hypothesis. The technical characteristics of the equipment can greatly affect annoyance, sense of oppression, pain. The technological proposals to reduce the discomfort of the patients concern various items: flexible compressors, self-compression devices under the supervision of the technician who performs the positioning and the minimum initial compression, environmental factors such as equipment noise reduction, chromatic, sound and sensory effects (eg: aromatic diffusers).

The aim of our study is to evaluate the effectiveness of the self-compression compared to the standard one, in reducing annoyance, a sense of oppression and pain, and to evaluate the difference of the average glandular dose given to the woman for each projection.

Self-compression may help reaching better compression tolerating the discomfort and pain induced thus allowing to achieve a lower thickness, a lower glandular dose and a better image.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

502

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • RE
      • Reggio Emilia, RE, Italy, 42123
        • Laura Canovi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women in follow-up after surgery
  • Symptomatic women undergoing mammography
  • Early diagnosis in asymptomatic women outside the organized screening program (these women are predominantly aged 40-44 / 75-85)
  • Women with familiar risk

Exclusion Criteria:

  • Augmentation prostheses
  • Women in screening with active invitation
  • Physical impossibility to use the self-compression command
  • Inability to provide consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1. Self-compression arm
Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
NO_INTERVENTION: 2. Control arm
The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average glandular dose administered (mSv)
Time Frame: This outcome is measured at the baseline mammography.
Average glandular dose administered during mammography is automatically computed by the machine according to an algorithm using the data on the quantity of radiation emitted and the radiation captured by the detector.
This outcome is measured at the baseline mammography.
Image quality: radiographers' scale.
Time Frame: This outcome is measured at the baseline mammography.
Radiographers evaluate the image quality after exam with a radiographer specific 3-item scale (contrast, resolution, compression) on a 0 to 5 point scale. Higher values mean better quality.
This outcome is measured at the baseline mammography.
Image quality: radiologists' scale.
Time Frame: This outcome is measured at the baseline mammography.
Radiologists evaluate the image quality after exam a radiologist specific 3-item scale (contrast, resolution, compression) on a 0 to 5 point scale. Higher values mean better quality.
This outcome is measured at the baseline mammography.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breast thickness at the time of exposure (cm)
Time Frame: This outcome is measured at the baseline mammography.
Breast thickness is measured automatically by the machine. This endpoint will be evaluated using single exposure as statistical unit, taking into account the autocorrelation of the 4 exposures in the same woman.
This outcome is measured at the baseline mammography.
Maximum compression (daN)
Time Frame: This outcome is measured at the baseline mammography.
Compression is measured automatically by the machine. This endpoint will be evaluated using single exposure as statistical unit, taking into account the autocorrelation of the 4 exposures in the same woman.
This outcome is measured at the baseline mammography.
Pain during compression
Time Frame: pain will be evaluated immediately after baseline mammography execution
visual assessment scale
pain will be evaluated immediately after baseline mammography execution
Memory of pain in previous mammography
Time Frame: before the follow up mammography, i.e. approximately 1 year after baseline mammography
visual assessment scale
before the follow up mammography, i.e. approximately 1 year after baseline mammography
Anxiety
Time Frame: Anxiety will be measured just before the baseline mammography and before the follow up mammography, i.e. approximately 1 year after baseline mammography.

questionnaire: State Trait Anxiety Inventory for adults - form Y (D. Spielberger).

The scale has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale. Higher scores indicate greater anxiety.

Anxiety will be measured just before the baseline mammography and before the follow up mammography, i.e. approximately 1 year after baseline mammography.
Discomfort
Time Frame: Discomfort will be measured just after the baseline mammography.
Discomfort will be measured with a one-item scale with five-point range (no, slight, moderate, considerable and severe discomfort).
Discomfort will be measured just after the baseline mammography.
Execution time of the exam:
Time Frame: This outcome is measured at the baseline mammography.

We evaluate: - total time (from randomization to close examination). Times are automatically registered by the radiology information system.

- Second breast time (from the acquisition of the second right breast projection to the acquisition of the second left breast projection)

This outcome is measured at the baseline mammography.
Participation in follow up mammography
Time Frame: 1 year (+/- 2 months) after baseline mammography
Number of women presenting to follow up mammography (1 year +/-2 months)/number of recruited women referred to follow up mammography after 1 year
1 year (+/- 2 months) after baseline mammography

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laura Canovi, RT, Arcispedale S.Maria Nuova

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 25, 2018

Primary Completion (ACTUAL)

July 31, 2019

Study Completion (ACTUAL)

December 31, 2020

Study Registration Dates

First Submitted

January 9, 2019

First Submitted That Met QC Criteria

July 2, 2019

First Posted (ACTUAL)

July 5, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 26, 2021

Last Update Submitted That Met QC Criteria

February 25, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • RCT Pristina 2/TR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The differences in average glandular dose between the two groups will be compared with a student test if the distributions can be assimilated to a normal one and with non-parametric test in case of non-normality of the distributions.

If the average glandular dose is not lower in the study group (superiority test) and / or the proportion of women with suboptimal compression (<10daN) and> = in the experimental group, the image quality measured with a qualitative subjective scale of the radiologist with a non-parametric test (superiority test).

For secondary endpoints, the results will be compared between the two arms with student tests for the medium with normal distribution, non-parametric tests for non-normal distributions, while for the proportions a chi-square test will be performed.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Self compression arm

3
Subscribe